Serves as Model
Retinoblastoma requires early detection if the child’s sight is to be saved. But not every child in an RB family will develop tumors—it depends on whether he or she inherits certain mutations. Currently, each child in a family suspected to have a mutation in the RB gene must be examined every three months to see if a tumor has developed.
Under the age of three, the child must be anesthetized, and each exam can cost as much as $1,000, or about $50,000 for an average family over the first three years of their children’s lifetimes. Clearly, a better alternative is to detect which children have inherited the disease-causing mutation and monitor only those at risk. But developing a cost-effective way of detecting the RB gene suitable for routine hospital laboratory practice posed major challenges.
The RB gene consists of 27 stretches of DNA scattered among a total of 200,000 base pairs. The current procedure for detecting RB, the single stranded conformation polymorphism technique, is laborious and time consuming—one test involving one family can take from 6 to 12 months. For many hospitals, this is unaffordable on a routine basis. This method also “seemed to us to require a high level of interpretation,” says Dr. Gallie. “We simply couldn’t see how this technology could ever become a service tool.”
The integrated system developed by Pharmacia Biotech and ERIC collaborators consists of five elements: DNA extraction and purification; gene amplification; a Decipher™ kit for processing the sequence reactions; a SBD A.L.F. automated DNA analyzing unit for reading the sequence; and SBD presentation of the results. SBD incorporates major technical advances, says Pharmacia’s Steven Chackowicz, who worked with the ERIC team in developing the technology. Key steps have been automated, and Pharmacia has provided software prompting the clinical technologist on what follows next.
The development of special kits has all but eliminated laborious pipetting and the chance of human error from many stages in the process. For instance, the Decipher kits are based on a patented Pharmacia process of vitrification which involves “glassifying” the reaction enzymes and other heat labile products. This ensures their stability at room temperatures and eliminates the need to store them in the freezer.
Pharmacia links these reaction enzymes to plastic microtiter plates as well as specially designed “combs” bearing primers. The technologist then adds water to the wells and dips the primer-bearing comb into the wells where the reaction then takes place. To read the sequence, the technologist places the comb in the A.L.F. automated sequencer.
Altogether, it takes about one day for one RB patient (24 samples) to be processed, a far cry from the months it used to take. Where it now takes $50,000 to assess one family for three years, the cost could drop to as little as $1,000, according to Dr. Gallie.
But SBD solves another major problem with automated sequencing: the high background noise obscuring the signal, leading to inaccuracies.
Scientists have tended to distrust such results, and Chackowicz believes this is a major reason why the technology has not flourished within the research community. In other processes, the labeled samples contain all four fluorescent tags—one each for adenine, cytosine, thymine and guanine. “These four labels have overlapping emissions,” says Chackowicz, creating the bothersome background noise.
The SBD system, instead, divides the sample into four lanes, one for each type of base. This advance, along with a fixed laser beam reading the results, provides better signal and less noise.
Not all parts of the system are ready for commercial use, says Chackowicz, but he anticipates a complete package ready for reading the RB gene in about 12 months. The company has begun submissions to the FDA and other regulatory agencies for approval.
Dr. Gallie sees as future goals developing SBD for more common diseases, such as genetically-linked forms of breast cancer and colon tumors. Other applications may include congenital adrenal hyperplasia, certain forms of heart disease, and tissue typing. She emphasizes, however, that SBD is not designed for screening healthy populations. The gene must be well characterized first, she says, and patients should be at some risk of developing the disease or show early symptoms.
Per Lindstrom, Ph.D., director of molecular diagnostic market development at Pharmacia, says, “We start with the clinicians—they want better diagnostic procedures, and better treatments to put in place.” SBD is linked to treatment, no population genetics.
“There has to be an outcome for the patient, either in lifestyle changes or in better therapies. It’s the only way to get the technology accepted by the clinician,” adds Maggie Bywater, M.D., Ph.D., deputy director, molecular diagnostic market development at Pharmacia.